Insights from discovery through clinical efficacy to support a new class of therapeutics in Alzheimer’s disease

Research into innovative small molecule therapeutics with disease modifying potential in Alzheimer’s disease (AD) has been conducted at Alzheon since 2013.

This research and development has yielded a novel clinical candidate, ALZ-801, a phase 3-ready, first-in-class, small molecule oral inhibitor of amyloid aggregation and neurotoxicity – hallmarks of AD. ALZ-801 emerged as a drug candidate through the re-evaluation of tramiprosate, the active molecule of a prodrug ALZ-801, which had been previously studied for the treatment of AD in two large phase 3 studies in North America and Europe, and demonstrated a favourable safety profile but failed to show conclusive clinical efficacy in the overall Alzheimer’s population. ALZ-801 is a novel optimised prodrug of tramiprosate based on insights into tramiprosate’s mechanism of action and clinical results in genetically-defined subset of AD patients.

As quoted from  Read the full article here or download the PDF below
2017-09-13T17:32:05+00:00June 2nd, 2017|Tags: |